| Ticker | Current Price | % Daily Change | Volume (1,000s) | Average Volumn (1,000s) | Market Cap (Millions) | 1/2/2024 Price | % Change Since Inception 1/2/2024 |
|---|---|---|---|---|---|---|---|
| AVTE | $2.67 | 1.521% | 110 | 787 | $77 | $21.81 | -87.8% |
Aerovate Therapeutics, Inc.
930 Winter Street
Suite M-500
Waltham, MA 02451
United States
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate’s initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.